Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
September 03, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024 16:01 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Appointment of Alan Huang, PhD, as Vice President of Sales
September 03, 2024 09:02 ET
|
Polarean
DURHAM, NC and LONDON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical device leader in advanced Magnetic Resonance...
Compass Therapeutics to Participate in Upcoming Investor Events
September 03, 2024 08:00 ET
|
Compass Therapeutics
BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Tourmaline Bio to Present at Upcoming Investor Conferences
September 03, 2024 07:45 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Present at Upcoming Investor Conferences
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024
September 03, 2024 07:30 ET
|
23andMe, Inc.
Preliminary data from renal cancer and TMB-H/MSI-H cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Analysis of CD200 as an exploratory tissue-based biomarker associated with...
Fractyl Health to Participate in Upcoming September Investor Conferences
September 03, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Participate in Upcoming September Investor Conferences
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
September 02, 2024 18:40 ET
|
Vaxcyte, Inc.
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the...
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
August 29, 2024 08:00 ET
|
Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025
August 29, 2024 07:30 ET
|
Big4Bio
New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week